8-K: LAVA Therapeutics Faces Nasdaq Delisting Notice After Share Price Drops Below $1.00

LAVA Therapeutics N.V. received a notification from Nasdaq on February 27, 2025, indicating non-compliance with the minimum bid price requirement, as its common shares traded below $1.00 for 30 consecutive business days.

Summary

• LAVA Therapeutics N.V. received a notice from Nasdaq on February 27, 2025, stating that it is not in compliance with Nasdaq Listing Rule 5450(a)(1).
• The company's common shares have traded below $1.00 per share for 30 consecutive business days.
• This notification does not immediately affect the listing or trading of the company's shares on the Nasdaq Global Select Market.
• LAVA Therapeutics has a 180-calendar day grace period, until August 26, 2025, to regain compliance by having its share price meet or exceed $1.00 for at least ten consecutive business days.
• If the company fails to regain compliance by August 26, 2025, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• To qualify for the additional period, the company must meet continued listing requirements for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the bid price requirement.
• The company would also need to provide written notice of its intention to cure the bid price deficiency, potentially through a reverse stock split.
• If Nasdaq believes the company cannot cure the deficiency or is otherwise ineligible, it will provide notice that the company's shares will be subject to delisting, which the company can appeal.
• LAVA Therapeutics intends to actively monitor its share price and consider available options to regain compliance.
• There is no assurance that the company will regain compliance or receive a further extension.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice from Nasdaq, indicating financial distress and potential challenges for the company's future.

Positives

• The notification of noncompliance has no immediate effect on the listing or trading of the company's common shares on The Nasdaq Global Select Market.
• LAVA Therapeutics has a grace period of 180 calendar days to regain compliance.
• The company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.

Negatives

• LAVA Therapeutics is not in compliance with Nasdaq Listing Rule 5450(a)(1).
• The company's share price has been below $1.00 for 30 consecutive business days.
• Failure to regain compliance could lead to delisting from the Nasdaq Global Select Market.

Risks

• There is no assurance that LAVA Therapeutics will be able to regain compliance with Nasdaq's listing requirements.
• Nasdaq may not grant the company a further extension of time to regain compliance.
• Delisting from the Nasdaq Global Select Market could negatively impact the company's stock price and investor confidence.

Future Outlook

The company intends to actively monitor the bid price of its common shares and will consider available options to regain compliance with the listing requirements. There can be no assurance that the Company will be able to regain compliance with Nasdaqs Listing Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq listing criteria, or that Nasdaq will grant the Company a further extension of time to regain compliance, if applicable.

Management Comments

• Fred Powell, Chief Financial Officer, signed the report on behalf of LAVA Therapeutics, N.V.

Industry Context

Many biotech companies, especially those in the early stages of development, can face share price volatility and the risk of falling below minimum bid price requirements. This situation is not uncommon, and companies often explore options like reverse stock splits or transferring to a different market to maintain their listing.

Comparison to Industry Standards

• Many companies in the biotechnology sector, particularly smaller firms with limited revenue, face challenges in maintaining share price compliance with Nasdaq listing requirements.
• Reverse stock splits are a common strategy employed by companies in similar situations to artificially increase the share price and meet the minimum bid requirement.
• Companies like Geron Corporation and Ocugen Inc. have previously faced similar delisting warnings and implemented reverse stock splits to regain compliance.
• The success of these strategies varies, and ultimately depends on the company's underlying financial performance and investor confidence.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty about the company's future.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• LAVA Therapeutics will actively monitor the bid price of its common shares.
• The company will consider available options to regain compliance with the listing requirements.
• The company may consider a reverse stock split.

Key Dates